MedTrace Logo

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

NCT00963365 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2014-10-13

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of AZD6765 when given in single and multiple oral doses and to compare an oral and intravenous (IV) formulation of AZD6765 to placebo.

Conditions

  • Healthy

Interventions

DRUG

AZD6765

Single oral dose and single IV infusion of AZD6765

DRUG

AZD6765

Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.

Sponsors & Collaborators

Principal Investigators

  • Phillip Leese, MD · Quintiles, Inc.

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-02-28
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00963365 on ClinicalTrials.gov